TAK242抑制Toll样受体4通路对脓毒症大鼠肝脏的保护作用
该研究将18只雄性SD大鼠随机分为三组(每组6只),以腹腔注射脂多糖15 mg/kg建立脓毒症模型,TAK242干预组在建模前腹腔注射TAK242 5 mg/kg,模型组与对照组注射等量溶剂(10%二甲基亚砜+90%玉米油)。6小时后采集腹主动脉血检测ALT、AST,取肝组织用蛋白质印迹法检测TLR4、TNF-α、IL-6、caspase-3、NF-κB p65及磷酸化NF-κB p65,并行免疫组化与HE染色。结果显示TAK242干预组ALT、AST及上述炎症与凋亡指标均显著低于脓毒症模型组,肝细胞排列更整齐、水肿与炎性细胞浸润明显减轻。作者结论为TAK242通过抑制TLR4/NF-κB通路减轻脓毒症大鼠肝损伤、保护肝脏,属动物实验证据。
要点
- 脓毒症模型组血清ALT(μg/L)26.639±7.814 vs 对照组2.847±2.150、AST 28.442±8.417 vs 5.779±3.019,均P<0.01,提示造模后肝损伤。
- TAK242干预组ALT(μg/L)7.269±3.398 vs 模型组26.639±7.814、AST 3.580±3.115 vs 28.442±8.417,均P<0.01,肝酶较模型组显著降低。
- TAK242干预组肝组织IL-6/GAPDH 1.035±0.042 vs 模型组1.442±0.204、TNF-α/GAPDH 0.572±0.096 vs 1.089±0.098、TLR4/GAPDH 0.984±0.078 vs 1.292±0.085、p-NF-κB p65/NF-κB p65比值1.484±0.255 vs 1.936±0.081,均P<0.05。
- caspase-3/GAPDH:模型组0.794±0.164 vs 对照组0.482±0.055(P<0.05),TAK242干预组0.482±0.056 vs 模型组0.794±0.164(P<0.05),提示TAK242可减轻脓毒症大鼠肝细胞凋亡。
- HE染色示模型组肝细胞排列紊乱、细胞水肿明显、炎性细胞浸润增多,TAK242干预组肝细胞排列较整齐、水肿明显减轻、炎性细胞浸润减少。
适用人群与场景
- 雄性Sprague-Dawley(SD)大鼠,共18只,随机分为三组、每组6只。
- 脓毒症模型经腹腔注射脂多糖15 mg/kg建立;TAK242干预组在建模前腹腔注射TAK242 5 mg/kg。
- 模型组与对照组注射等量溶剂(10%二甲基亚砜+90%玉米油)。
处置流程与药物剂量
- TAK242干预组于建模前腹腔注射TAK242 5 mg/kg。
- 建模6小时后采集腹主动脉血,用酶联免疫吸附法(ELISA)检测血清ALT、AST。
- 采血后处死大鼠取肝组织,用蛋白质印迹法检测TLR4、TNF-α、IL-6、caspase-3、NF-κB p65及p-NF-κB p65,用免疫组化观察NF-κB p65表达,用HE染色评估肝细胞损伤。
研究设计与关键结果
- 动物实验:18只雄性SD大鼠随机分为对照组、脓毒症模型组、TAK242干预组,每组6只,模型经腹腔注射脂多糖15 mg/kg建立。
- 血清ALT(μg/L):模型组26.639±7.814 vs 对照组2.847±2.150,P<0.01;TAK242干预组7.269±3.398 vs 模型组26.639±7.814,P<0.01。
- 血清AST(μg/L):模型组28.442±8.417 vs 对照组5.779±3.019,P<0.01;TAK242干预组3.580±3.115 vs 模型组28.442±8.417,P<0.01。
- caspase-3/GAPDH:模型组0.794±0.164 vs 对照组0.482±0.055,P<0.05;TAK242干预组0.482±0.056 vs 模型组0.794±0.164,P<0.05。
- IL-6/GAPDH:模型组1.442±0.204 vs 对照组1.019±0.024,P<0.05;TAK242干预组1.035±0.042 vs 模型组1.442±0.204,P<0.05。
- TNF-α/GAPDH:模型组1.089±0.098 vs 对照组0.806±0.005,P<0.05;TAK242干预组0.572±0.096 vs 模型组1.089±0.098,P<0.05。
- TLR4/GAPDH:模型组1.292±0.085 vs 对照组0.941±0.087,P<0.05;TAK242干预组0.984±0.078 vs 模型组1.292±0.085,P<0.05。
- p-NF-κB p65/NF-κB p65比值:模型组1.936±0.081 vs 对照组1.579±0.183,P<0.05;TAK242干预组1.484±0.255 vs 模型组1.936±0.081,P<0.05;免疫组化示模型组NF-κB p65阳性表达较对照组明显增多,TAK242干预组较模型组明显减少、胞核几乎无阳性表达。
证据类型、等级与局限
- 证据类型:动物实验(大鼠脓毒症模型),每组6只。
- 作者结论:TAK242可通过抑制TLR4/NF-κB通路减轻脓毒症大鼠肝损伤、保护肝脏。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文为脂多糖诱导脓毒症大鼠的动物实验,TAK242 5 mg/kg建模前腹腔注射可降低ALT、AST并抑制TLR4/NF-κB通路,尚不能直接转化为急诊/ICU临床用药做法。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To investigate the protective mechanism of TAK242, a specific inhibitor of Toll-like receptor 4 (TLR4), on the liver of septic rats.
METHODS: Eighteen male Sprague-Dawley (SD) rats were randomly divided into three groups (n = 6 in each group). The septic model was established by intraperitoneal injection of lipopolysaccharide (LPS) 15 mg/kg. The rats in the TAK242 intervention group received intraperitoneal injection of TAK242 (5 mg/kg) before modeling, while the rats in the septic model group and the control group were injected with the same amount of solvent [10% dimethyl sulfoxide (DMSO)+90% corn oil]. Six hours later, the blood of abdominal aorta was collected and the levels of serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were measured by enzyme linked immunosorbent assay (ELISA). The rats were sacrificed to obtain liver, the expression levels of TLR4, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), cysteinyl aspartate-specific proteinase-3 (caspase-3), nuclear factor-κB p65 (NF-κB p65) and phosphorylated NF-κB p65 (p-NF-κB p65) were detected by Western blotting. Immunohistochemical staining was used to observe NF-κB p65 protein expression in liver, and hepatocyte injury was assessed by hematoxylin-eosin (HE) staining.
RESULTS: Serum ALT and AST levels in the septic model group were significantly higher than those in the control group [ALT (μg/L): 26.639±7.814 vs. 2.847±2.150, AST (μg/L): 28.442±8.417 vs. 5.779±3.019, both P < 0.01]. The ALT and AST levels in the TAK242 intervention group were significantly lower than those in septic model group [ALT (μg/L): 7.269±3.398 vs. 26.639±7.814, AST (μg/L): 3.580±3.115 vs. 28.442±8.417, both P < 0.01]. Light microscopy showed that the hepatocytes in the septic model group were disordered, with obvious cell edema and increased inflammatory cells infiltration; the hepatocytes in the TAK242 intervention group were more neatly arranged, with significantly reduced hepatocyte edema and reduced inflammatory cells infiltration. Western blotting results showed that caspase-3 protein expression in hepatic tissue of septic model group was significantly higher than that in the control group (caspase-3/GAPDH: 0.794±0.164 vs. 0.482±0.055, P < 0.05), and caspase-3 protein expression in the TAK242 intervention group significantly decreased than that in the septic model group (caspase-3/GAPDH: 0.482±0.056 vs. 0.794±0.164, P < 0.05), which indicated that TAK242 could attenuate hepatocytes apoptosis of septic rats. The expression of IL-6, TNF-α and TLR4 protein and the ratio of p-NF-κB p65/NF-κB p65 in hepatic tissue of septic model group were significantly higher than those in control group (IL-6/GAPDH: 1.442±0.204 vs. 1.019±0.024, TNF-α/GAPDH: 1.089±0.098 vs. 0.806±0.005, TLR4/GAPDH: 1.292±0.085 vs. 0.941±0.087, p-NF-κB p65/NF-κB p65 ratio: 1.936±0.081 vs. 1.579±0.183, all P < 0.05), IL-6, TNF-α and TLR4 protein expression and p-NF-κB p65/NF-κB p65 ratio in the TAK242 intervention group were significantly lower than those in septic model group (IL-6/GAPDH: 1.035±0.042 vs. 1.442±0.204, TNF-α/GAPDH: 0.572±0.096 vs. 1.089±0.098, TLR4/GAPDH: 0.984±0.078 vs. 1.292±0.085, p-NF-κB p65/NF-κB p65 ratio: 1.484±0.255 vs. 1.936±0.081, all P < 0.05), it is suggested that LPS-induced sepsis could activate the inflammatory response mediated by TLR4/NF-κB pathway in liver, and the activation of TLR4/NF-κB pathway was inhibited by TAK242 through the TLR4 pathway, therefore, the inflammation of liver in septic rats was reduced. Immunohistochemical staining showed that the positive expression of NF-κB p65 in liver was significantly increased in the septic model group compared with the control group; the positive expression of NF-κB p65 was significantly reduced in the TAK242 intervention group compared with the septic model group, and there was almost no positive expression in the nucleus.
CONCLUSIONS: TAK242 could reduce liver function injury and protect the liver by inhibition TLR4/NF-κB pathway in septic rats.
参考来源
- Yang M, Liu Z, Xu Z, et al. [Inhibition of Toll-like receptor 4 pathway by TAK242 protects the liver in sepsis]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2022. PMID: 36177923. doi:10.3760/cma.j.cn121430-20220420-00395
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。